Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) EBIT (2016 - 2025)

Historic EBIT for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q3 2025 value amounting to -$31.3 million.

  • Vanda Pharmaceuticals' EBIT fell 18440.0% to -$31.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$121.1 million, marking a year-over-year decrease of 22313.28%. This contributed to the annual value of -$40.7 million for FY2024, which is 19142.78% down from last year.
  • As of Q3 2025, Vanda Pharmaceuticals' EBIT stood at -$31.3 million, which was down 18440.0% from -$38.5 million recorded in Q2 2025.
  • In the past 5 years, Vanda Pharmaceuticals' EBIT registered a high of $12.4 million during Q2 2021, and its lowest value of -$41.0 million during Q1 2025.
  • Its 5-year average for EBIT is -$6.2 million, with a median of -$6.0 million in 2023.
  • Per our database at Business Quant, Vanda Pharmaceuticals' EBIT skyrocketed by 837280.0% in 2021 and then plummeted by 56082.83% in 2024.
  • Over the past 5 years, Vanda Pharmaceuticals' EBIT (Quarter) stood at $8.6 million in 2021, then dropped by 23.24% to $6.6 million in 2022, then crashed by 207.01% to -$7.1 million in 2023, then crashed by 44.9% to -$10.3 million in 2024, then plummeted by 204.35% to -$31.3 million in 2025.
  • Its EBIT stands at -$31.3 million for Q3 2025, versus -$38.5 million for Q2 2025 and -$41.0 million for Q1 2025.